FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740871976> ?p ?o ?g. }

• W2740871976 abstract "Background Alectinib, a highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), demonstrated a stunning disease control rate (95.7%) and unprecedented median progression-free survival (not reached: 95% CI: 20.3-) (Lancet Oncology 2013, ASCO 2016, Abstract #9008). However, acquired resistance to alectinib is inevitable; some ALK-positive lung tumors rapidly acquire alectinib resistance. Therefore, we sought to investigate the mechanism of the rapid resistance to alectinib using clinical samples and patient-derived ALK-positive cell lines. Materials and Methods Autopsied samples (primary lung tumors and metastatic tumors from the esophagus, liver, and bilateral kidney) were obtained from a 51-year-old male with advanced ALK-positive lung cancer. The lung tumors acquired resistance to first-line treatment of alectinib in three months, and subsequent treatment with ceritinib or crizotinib showed only a moderate and temporary effect. We established novel ALK-positive cell lines; ABC-14 was established from a pleural effusion after alectinib treatment, and ABC-17 was established from patient-derived xenograft (PDX) tumors of autopsied liver metastases. Western blot analysis, immunostaining, a receptor tyrosine kinase assay, fluorescence in situ hybridization (FISH), and next-generation sequencing were performed. Results ALK overexpression was confirmed in all autopsied samples by immunostaining. PCR revealed that ABC-14 harbored the EML-4/ALK fusion variant 3. An in vitro cell proliferation assay showed that ABC-14 exhibited resistance to alectinib (IC 50 > 1 µM), but was sensitive to crizotinib (IC 50 = 98 nM). The receptor tyrosine kinase assay revealed the activation of MET and EGFR in ABC-14. Quantitative RT-PCR and FISH confirmed MET gene amplification. Quantitative RT-PCR also indicated the overexpression of an EGFR ligand, EGF, TGF-α but no EGFR mRNA overexpression. The combination of crizotinib (dual ALK/MET-TKI) and an EGFR-TKI, gefitinib, showed an additive inhibitory effect on cell growth compared with each drug alone in vitro. ABC-17 showed resistance to both alectinib and crizotinib; consistently showed no activation of MET and no MET gene amplification. Interestingly, ABC-17 showed metastatic ability in the lung in NOG mouse PDX models. Conclusion The mechanism of rapid resistance to alectinib may be complicated and heterogeneous. Crizotinib combined with gefitinib, which inhibits the ALK, EGFR, and MET pathways, may represent one potent strategy against alectinib resistance. Further next-generation sequencing of clinically relevant samples should provide deeper insights into its resistance. (This work was supported by KAKEN 16K19454 and KAKEN 15H04830.) Citation Format: Go Makimoto, Kadoaki Ohashi, Kazuya Nishii, Shuta Tomida, Hiroe Kayatani, Tomoki Tamura, Hisao Higo, Kiichiro Ninomiya, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura. A comprehensive analysis of autopsied specimens and patient-derived cell lines in ALK-positive lung cancers with rapid acquired resistance to alectinib [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3164. doi:10.1158/1538-7445.AM2017-3164" @default.
• W2740871976 created "2017-08-08" @default.
• W2740871976 creator A5001706604 @default.
• W2740871976 creator A5002407044 @default.
• W2740871976 creator A5014194149 @default.
• W2740871976 creator A5019511958 @default.
• W2740871976 creator A5033361967 @default.
• W2740871976 creator A5036685872 @default.
• W2740871976 creator A5039723911 @default.
• W2740871976 creator A5050389295 @default.
• W2740871976 creator A5052265261 @default.
• W2740871976 creator A5056975051 @default.
• W2740871976 creator A5062920555 @default.
• W2740871976 creator A5066700160 @default.
• W2740871976 creator A5068740298 @default.
• W2740871976 creator A5076072180 @default.
• W2740871976 creator A5091805928 @default.
• W2740871976 date "2017-07-01" @default.
• W2740871976 modified "2023-09-26" @default.
• W2740871976 title "Abstract 3164: A comprehensive analysis of autopsied specimens and patient-derived cell lines in ALK-positive lung cancers with rapid acquired resistance to alectinib" @default.
• W2740871976 doi "https://doi.org/10.1158/1538-7445.am2017-3164" @default.
• W2740871976 hasPublicationYear "2017" @default.
• W2740871976 type Work @default.
• W2740871976 sameAs 2740871976 @default.
• W2740871976 citedByCount "1" @default.
• W2740871976 countsByYear W27408719762017 @default.
• W2740871976 crossrefType "proceedings-article" @default.
• W2740871976 hasAuthorship W2740871976A5001706604 @default.
• W2740871976 hasAuthorship W2740871976A5002407044 @default.
• W2740871976 hasAuthorship W2740871976A5014194149 @default.
• W2740871976 hasAuthorship W2740871976A5019511958 @default.
• W2740871976 hasAuthorship W2740871976A5033361967 @default.
• W2740871976 hasAuthorship W2740871976A5036685872 @default.
• W2740871976 hasAuthorship W2740871976A5039723911 @default.
• W2740871976 hasAuthorship W2740871976A5050389295 @default.
• W2740871976 hasAuthorship W2740871976A5052265261 @default.
• W2740871976 hasAuthorship W2740871976A5056975051 @default.
• W2740871976 hasAuthorship W2740871976A5062920555 @default.
• W2740871976 hasAuthorship W2740871976A5066700160 @default.
• W2740871976 hasAuthorship W2740871976A5068740298 @default.
• W2740871976 hasAuthorship W2740871976A5076072180 @default.
• W2740871976 hasAuthorship W2740871976A5091805928 @default.
• W2740871976 hasConcept C117643217 @default.
• W2740871976 hasConcept C121608353 @default.
• W2740871976 hasConcept C126322002 @default.
• W2740871976 hasConcept C142724271 @default.
• W2740871976 hasConcept C170493617 @default.
• W2740871976 hasConcept C2776232967 @default.
• W2740871976 hasConcept C2776256026 @default.
• W2740871976 hasConcept C2778347629 @default.
• W2740871976 hasConcept C2778820342 @default.
• W2740871976 hasConcept C2779220645 @default.
• W2740871976 hasConcept C2779422266 @default.
• W2740871976 hasConcept C2779750558 @default.
• W2740871976 hasConcept C42362537 @default.
• W2740871976 hasConcept C502942594 @default.
• W2740871976 hasConcept C71924100 @default.
• W2740871976 hasConceptScore W2740871976C117643217 @default.
• W2740871976 hasConceptScore W2740871976C121608353 @default.
• W2740871976 hasConceptScore W2740871976C126322002 @default.
• W2740871976 hasConceptScore W2740871976C142724271 @default.
• W2740871976 hasConceptScore W2740871976C170493617 @default.
• W2740871976 hasConceptScore W2740871976C2776232967 @default.
• W2740871976 hasConceptScore W2740871976C2776256026 @default.
• W2740871976 hasConceptScore W2740871976C2778347629 @default.
• W2740871976 hasConceptScore W2740871976C2778820342 @default.
• W2740871976 hasConceptScore W2740871976C2779220645 @default.
• W2740871976 hasConceptScore W2740871976C2779422266 @default.
• W2740871976 hasConceptScore W2740871976C2779750558 @default.
• W2740871976 hasConceptScore W2740871976C42362537 @default.
• W2740871976 hasConceptScore W2740871976C502942594 @default.
• W2740871976 hasConceptScore W2740871976C71924100 @default.
• W2740871976 hasLocation W27408719761 @default.
• W2740871976 hasOpenAccess W2740871976 @default.
• W2740871976 hasPrimaryLocation W27408719761 @default.
• W2740871976 hasRelatedWork W1502103045 @default.
• W2740871976 hasRelatedWork W1552307519 @default.
• W2740871976 hasRelatedWork W1971263545 @default.
• W2740871976 hasRelatedWork W1973016854 @default.
• W2740871976 hasRelatedWork W2126927831 @default.
• W2740871976 hasRelatedWork W2145472255 @default.
• W2740871976 hasRelatedWork W2319183095 @default.
• W2740871976 hasRelatedWork W2488304274 @default.
• W2740871976 hasRelatedWork W2512042252 @default.
• W2740871976 hasRelatedWork W2911022307 @default.
• W2740871976 hasRelatedWork W2954109966 @default.
• W2740871976 hasRelatedWork W2955522989 @default.
• W2740871976 hasRelatedWork W2965590398 @default.
• W2740871976 hasRelatedWork W2999090889 @default.
• W2740871976 hasRelatedWork W3003150412 @default.
• W2740871976 hasRelatedWork W3016506404 @default.
• W2740871976 hasRelatedWork W3027882342 @default.
• W2740871976 hasRelatedWork W3111588936 @default.
• W2740871976 hasRelatedWork W3195755339 @default.
• W2740871976 hasRelatedWork W3197171273 @default.
• W2740871976 isParatext "false" @default.
• W2740871976 isRetracted "false" @default.
• W2740871976 magId "2740871976" @default.
• W2740871976 workType "article" @default.